Spyre Therapeutics (SYRE) Non-Current Deffered Revenue (2021 - 2023)

Spyre Therapeutics has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $2.3 million in Q2 2023.

• For the quarter ending Q2 2023, Non-Current Deffered Revenue fell 1.31% year-over-year to $2.3 million; the trailing twelve-month figure through Jun 2023 stood at $2.3 million (down 1.31% YoY), and the FY2022 full-year result was $2.2 million, up 79.05% from the prior year.
• Non-Current Deffered Revenue for Q2 2023 stood at $2.3 million, roughly flat from $2.3 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $2.4 million in Q2 2022, with the low at $740000.0 in Q1 2022.
• Historically, Non-Current Deffered Revenue has averaged $2.0 million across 3 years, with a median of $2.2 million in 2021.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue slumped 67.46% — and 2023, when it jumped 216.35%.
• Spyre Therapeutics' Non-Current Deffered Revenue stood at $1.2 million in 2021, then surged by 79.05% to $2.2 million in 2022, then grew by 7.43% to $2.3 million in 2023.
• The last three Non-Current Deffered Revenue figures came in at $2.3 million (Q2 2023), $2.3 million (Q1 2023), and $2.2 million (Q4 2022), per Business Quant data.